China Reports Success In Anti-Kickback Effort In Drug Sector
This article was originally published in PharmAsia News
Chinese authorities say kickbacks by drug makers to physicians who prescribe their drugs contributed to illicit revenue that has totaled more than $5.5 million since November 2007. The report by the Communist Party of China Central Commission for Discipline Inspection covers the period since China launched an anti-corruption clampdown. One of the methods it used was to adopt a bidding system for municipalities, provinces and autonomous regions to procure drugs, with 90 percent of prescriptions supplied under that system. The report also cited new regulations on the pricing and registration of drugs as helping to prevent corruption. (Click here for more
You may also be interested in...
The US FDA issued only one device-related close-out letter in October.
Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.